<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1123694601002921&amp;ev=PageView&amp;noscript=1">

Medical Systems News

Taiwan's government organization decides to stockpile Fujifilm's anti-influenza drug “Avigan® Tablet” —Fujifilm supplies Avigan® Tablet to Taiwan—

FUJIFILM Corporation (President: Shigehiro Nakajima) has announced that it provided, on July 13, a shipment of the anti-influenza drug Avigan® Tablet 200mg (Favipiravir, hereinafter “Avigan Tablet”) to Taiwan's government organization in charge of infectious disease control, called the Centers for Disease Control, R.O.C. (Taiwan) (hereinafter “Taiwanese CDC”), following its decision to stockpile Avigan Tablet. The Taiwanese CDC made the decision to protect Taiwanese citizens from the risk of new strains of influenza including avian and swine influenzas due to a growing possibility of its human transmission in Taiwan. Taiwan's Food and Drug Administration has yet to approve the manufacturing and marketing of Avigan Tablet at this stage, but the Taiwanese CDC has decided the import of the experimental drug exceptionally in recognition of its new mechanism of action and other benefits.

Read More

Topics: Corporate, News Releases

Fujifilm signs an exclusive market agreement with Chinese major pharmaceutical company Shenzhen Main Luck for the distribution of its oral synthetic quinolone antibacterial agent.

FUJIFILM Corporation (President: Shigehiro Nakajima; Hereinafter “Fujifilm”) has announced that it signed an exclusive marketing agreement with China's major pharmaceutical company Shenzhen Main Luck Pharmaceuticals Inc. (President: Yuan Qing; Hereinafter “Shenzhen Main Luck”) on June 26, 2015 for the oral synthetic quinolone antibacterial agent “T-3811” (generic name: garenoxacin mesilate hydrate), developed by the Fujifilm Group company Toyama Chemical Co., Ltd(Hereinafter “Toyama Chemical”).
Fujifilm now plans to start marketing T-3811 via Shenzhen Main Luck after obtaining import drug license for the drug in China. This will be the first time for Fujifilm to market a pharmaceutical product overseas.

Read More

Topics: Corporate, News Releases

Fujifilm acquires the U.S. medical IT software company TeraMedica, Inc. to expand its healthcare IT business

FUJIFILM Corporation (President: Shigehiro Nakajima) has announced that it completed the acquisition, through the U.S. sales subsidiary FUJIFILM Medical Systems U.S.A., Inc., of the U.S. medical IT software company TeraMedica, Inc. (Milwaukee, Wisconsin; hereafter “TeraMedica”). TeraMedica offers archive solutions for managing and storing a range of digitized in-hospital clinical information*, including diagnostic images of Picture Archiving Communication System (PACS)** to movie file images. TeraMedica became a full 100% subsidiary of the FUJIFILM Group on May 11, 2015 (U.S. EDT).

Read More

Topics: Investor Relations, Corporate, News Releases

Synapse MIX - Medical Imaging Excellence
Contact a Fujifilm Rep